Nexium Naproxen Esomeprazole Lotrel |
Cisapride
Stimulant laxatives irritate colonic mucosa and promote peristalsis. They may also affect fluid and electrolyte absorption resulting in colonic fluid accumulation. Bisacodyl is a useful rescue agent when managing chronic constipation. Stool softeners such as docusate soften stools by reducing the surface tension at the oil-water interface of fecal matter allowing water to penetrate. They are only of marginal value in treating constipation. Sorbitol and lactulose are non-absorbable carbohydrates that remain in the gastrointestinal tract and have an osmotic effect. They increase the water content of stool and soften stool. Their usefulness is limited by their fermentation, which results in discomfort, bloating, flatus, and explosive diarrhea. High molecular weight polyethylene glycol PEG ; obligates intraluminal water. PEG is a large polymer with substantial osmotic activity. PEG is used with balanced electrolytes in solution for colon cleansing as polyethylene glycol lavage solution PEG-ELS, GoLYTELYTM ; and Colyte, and sulfate-free electrolyte lavage solution SF-ELS, NuLYTELYTM ; . These solutions have been shown to be safe and effective in preparations for colonoscopy, barium xray examinations, and colon surgery. PEG-ELS and SF-ELS are isotonic, poorly absorbed solutions that pass the gastrointestinal tract with no net water or ion absorption or secretion. PEG-ELS and SF-ELS reach a steady-state equilibrium when given at high infusion rates of 1.5 L hour. When PEG-ELS and SF-ELS are used in smaller volumes to treat constipation, the steady state is not reached and the salts are absorbed, negating the safe intent of balanced lavage. PEG 3350 is a chemically inert polymer that does not contain any salt that can be absorbed. It is remarkably non-toxic and can be ingested in large amounts without any harmful effect. PEG 3350 is absorbed only in trace amounts from the gastrointestinal tract. In solution, PEG 3350 binds or sequesters water molecules. These osmotic effects make it an excellent candidate as a new laxative for constipation. Additional options for the management of constipation include colchicines and misoprotil. However, these are associated with side effects. Colchicine is a mucosal poison for gout. Misoprotil is a prostaglandin analog. Both agents are abortigenic and diarrheagenic. Recombinant brain-derived neurotrophic factor and neurotrophin-3 are investigational agents with promise. The 5-HT4 agonists, cisapride, prucalopride, and tegaserod, are effective but face regulatory obstacles to clinical use. Biofeedback and surgery are options for pelvic floor dysfunction. Surgical options for colonic inertia that fail to respond to medical management are also available. By their primary care physician for ADHD. The diagnosis of ADHD requires meeting DSM-IV criteria Table 1 ; . The assessment requires evidence obtained directly from parents caregivers regarding symptoms, age of onset, duration of symptoms, and degree of impairment. The assessment requires evidence obtained directly from classroom teachers regarding core symptoms, duration of symptoms, degree of impairment, and symptoms of coexisting conditions. Evaluation of children with ADHD should include assessment for coexisting conditions. Other diagnostic tests are not routinely indicated to establish the diagnosis of ADHD. ADHD is characterized by 2 core symptom areas--inattention and impulsivity hyperactivity. DSM-IV defines 9 characteristics for each of the 2 core symptom areas, with a diagnosis made when 6 or more symptoms from each core area are present and manifest for longer than 6 months. Table 2 presents the DSM-IV criteria for symptoms of inattention and of hyperactivity impulsivity. DSM-IV also includes several other subclassifications of ADHD, including: ADHD Combined Type 50% to 60% ; : criteria met for both inattention and impulsivity hyperactivity ADHD Predominantly Inattentive. Faeces in the rectum. Difficult and infrequent defaecation was associated with fever episodes I ; , and incomplete defaecation with proctalgia and bleeding, negatively with the ease of defaecation J ; . In another factor not shown ; familiary colon cancer and meteorism were loaded significantly. Finally the outcome of the treatment was tested on the dominating symptoms from Figure 1, Table 5 ; . Thus, a symptom could have disappeared or still be present or could still be absent or have arrived. The number of patients eligible for analysis were reduced, because some patients did not show up for the control or had moved away. Bloating, abdominal pressure and colics and epigastric discomfort were all reduced significantly. The process of defaecation was overall improved by significant reductions in incomplete- and repetitiveness, and now with ease and no pain and less liquid faeces. The results of treatment on physical signs and investigations were also tested. The presence of an abdominal mass in the right fossa fell from 42% to 17% p 0.05 ; , the associated tenderness from 58% to 27% p 0.05 ; and meteorism from 33% to 18% p 0.05 ; . Ano-rectal constipation was reduced significantly from 62% to 19% p 0.05 ; . C9sapride was administered to 159 patients 64% ; , minor headache or dizziness developing in 7%. Surgery was performed as follows: 76 patients with haemorrhoids grade 2 or more underwent banding or a Milligan-Morgan procedure, further four patients had an anal-fissure operated, and 20 patients had ano-rectal polyps removed; four patients underwent operation for a carcinoma. Macrolides clarithromycin, erythromycin, troleandomycin ; increase serum concentrations of cisapride. These locations. Our data are generally consistent with many of the previous observations on the effect of HTF 919 on the motor function of the gut in animals. The reason for the lack of a demonstrable concentration-related effect of the drug on patterns of motility of equine pelvic exure or ileum is unclear. The concentration range used may have been at the upper end of the concentration response curve, and the drug may act at sites other than 5-HT4 receptors at the higher concentrations used which might result in an inhibition of its potential to increase the contractility. Furthermore, the inhibiting effect of the selective 5-HT4 antagonist SB 203186 on 5-HT-induced contractions implies an involvement of the 5-HT4 receptor in equine gut motility. The maximal effect and the EC50 of HTF 919 compared with 5-HT plus tropisetron is about the same in ileal longitudinal preparations indicating that the effect on contractions in this localization of the intestine is mediated by 5-HT3 and 5-HT4 subreceptors see Fig. 3b ; . This was not observed in ileal circular specimens of equine intestine, where no effect of HTF 919 was observed see Fig. 3a ; . Still, our results are in contrast to the results of Nieto et al. 2000b ; , who reported no effect of the 5-HT4 receptor antagonist SDZ 205557 on 5-HT or cisapride induced contractions on equine jejunum. He suggested that the stimulatory effects of 5-HT on circular smooth muscle of equine jejunum are mediated, at least partially, by 5-HT2 and 5-HT3 receptors Nieto et al., 2000b ; . But a certain pattern of distribution of 5-HT receptor subtypes, established in one part of the intestine, cannot be conveyed to another part the intestine of the same species. Apart from species differences, heterogeneity among 5-HT4 receptors within a species, discovered in dog and guinea pig, is another possible explanation for varying effects of selective agonists in different tissues of the GI tract Mine et al., 1997 ; . Preliminary results from an in vivo study on healthy horses, HTF 919 was found to be effective in promoting gut motility R. Straub, personal communication ; whereas a signicant acceleration in small bowel transit could not be observed in dogs in vivo Nguyen et al., 1997 and propulsid. The association of a positive reinforcing drug with stimuli in the environment produces an increased preference for specific environmental stimuli as opposed to other similar stimuli this chapter; phillips & fibiger, this volume. As prodrugs, ppis are generally slow in onset, owing to their requirement for enteric coating to allow small-intestinal absorption, subsequent concentration in parietal-cell canaliculi, and eventual activation in an acidic environment and clemastine, for example, aspirin. In surveys conducted in South East Asia were found to be fakes Cockburn et al 2005, Dondorp et al 2004 ; . The case of artesunate is particularly important, because malaria parasites have become increasingly resistant to other medicines. In 2004 the US Institute of Medicine of the National Academies published a study entitled `Saving Lives, Buying Time: Economics of Malaria Drugs in an Age of Resistance'. This was the work of a committee chaired by the Nobel Prize Laureate and health economist Professor Kenneth Arrow. It called for international subsidies to be introduced to ensure that artemisinin based medicines are always supplied in combination with other anti-malarial products, in order to minimise the risk of resistance to this vital treatment developing. The sale of counterfeit drugs, with some perhaps containing partially effective doses, could deny the achievement of this shared social goal. The sale of fake anti-malarials already harms travellers such as European students visiting areas where malaria is endemic Newton 2006 ; . Similar tragedies occur in contexts such as the care of people with tuberculosis and HIV AIDS. They threaten not only Europeans who visit poorer countries. They also endanger those who might in Europe be exposed to resistant infections or the counterfeit substandard products often responsible for unchecked disease transmission in less advantaged regions. 12-week trials: mild and transient diarrhea 10.1% ; , headache 8.3% ; , abdomiF nal pain 7.4% ; , and flatulence 5.5% ; Table 2 ; . No deaths were reported. O Approximately 11% of patients disCH3 CH3 OH continued therapy because of ADEs; O O O N 3.5% withdrew because of diarrhea. As in H the 12-week trials, diarrhea was not asH NH2 O sociated with dehydration or electrolyte NH2 CH3 N Cp NH imbalances and did not result in any hospitalizations. Approximately 24% of Serotonin Tegaserod Cisaprids patients in this study had received previous tegaserod therapy. The rates of Figure 2 Chemical structures of serotonin, tegaserod, and cisapride. ADEs were generally similar in this group and in the group new to tegaserod therapy, although abdominal pain was reported more fresecretion, and it inhibits visceral sensitivity by selectively bindquently among tegaserod-naive patients 8.1% ; than among ing to 5-HT4 receptors.3538 It amplifies peristaltic reflexes withtegaserod-experienced patients 5.1% ; . out causing waves of nausea-evoking or pain-producing signals to be sent to the CNS because no 5-HT4 receptors are found on extrinsic sensor y ner ves.39 The probable presynaptic Ten-Week Study of Patients with Diarrhea location of 5-HT4 receptors in the gut also enables tegaserod Because the altered bowel function in patients with IBS can to increase motility in response to endogenous mucosal stimchange over time, a 10-week, randomized, double-blind, ulation without initiating constitutive, propulsive activity, which placebo-controlled study was performed to assess the safety tends to cause painful, incapacitating diarrhea if it occurs.39 of tegaserod in 86 patients 67% were women ; with at least a three-month history of IBS-D.6 ADEs were reported in 85.7% SAFETY TRIALS of patients receiving 2 mg twice daily, in 82.4% receiving 6 mg twice daily, and in 70.6% receiving placebo. No statistical difTegaserod has demonstrated significant beneficial effects in ference was noted between the tegaserod groups and the patients primarily women ; with IBS-C. In large, controlled, placebo group. randomized, phase 3 studies, tegaserod provided significantly With pooling of the data from the two tegaserod-treated greater overall improvement over placebo in relieving multigroups, the incidence of diarrhea was 33% vs. 35% in the ple and single symptoms of IBS-C, as described next. placebo group; P not significant ; , and the incidence of and clopidogrel. Pleasure, poverty, morality, commerce, and economics are but a few of the forces that have determined the fates of the drugs courtwright considers. And many of the alleged benefits and or safety advantages become muted within a short period of time. Table 1 presents the ten drugs with the highest DTC advertising budgets in 2000, representing 40% of advertising spending in that year and $16 billion in sales. What is the likely health benefit to U.S. consumers from most of these products? Meridia sibutramine ; was withdrawn from the Italian market in 2002 following reports of two deaths and more than 50 serious adverse reactions Reuters Health 2002 ; . Initial optimism about potential important safety advantages with Vioxx rofecoxib ; and Celebrex celecoxib ; appears unfounded, on the basis of the full reports of the results of large-scale safety trials Juni, Rutjes, and Dieppe 2002; Therapeutics Initiative 2001 2002 ; , and there is no evidence of superior efficacy in relieving the symptoms of arthritis than that offered by other nonsteroidal antiinflammatory drugs. Despite DTC advertisements that claim that paroxetine is "nonhabit forming, " withdrawal reactions have been reported following its use, including in infants exposed prenatally Vallis 2002 ; . Consumers in the United States have started a class-action lawsuit against Schering Plough, alleging that the company overstated the efficacy of Claritin loratadine ; in DTC advertising Lyles 2002 ; . Some drugs with significant levels of advertising to the U.S. public have been withdrawn for safety reasons, including Oraflex benoxaprofen ; , Rezulin troglitazone ; , Propulsid cisapride ; , and Baycol cerivastatin ; . These withdrawals call into question the assumption that new drugs will invariably have favorable benefit harm ratios and that consumers will benefit from hearing about them. Moreover, given this experience, why does Calfee 2002, p. 184 ; believe that it is reassuring that "just 29% [of respondents to the FDA survey] agreed that advertisements are allowed only for the `safest' prescription drugs?" Similarly, a California survey found that 43% of respondents believed that only completely safe drugs could be advertised to the public Bell, Kravitz, and Wilkes 1999 ; . In both cases, a substantial minority of the U.S. public wrongly believed that they were protected against harm from advertised products and cloxacillin. Pregnancy risk factor c lactation enters breast milk use caution aap rates compatible ; contraindications hypersensitivity to cisapride or any component of the formulations; gi hemorrhage, mechanical obstruction, gi perforation, or other situations when gi motility stimulation is dangerous serious cardiac arrhythmias including ventricular tachycardia, ventricular fibrillation, torsade de pointes, and qt prolongation have been reported in patients taking cisapride with other drugs that inhibit cyp3a some of these events have been fatal. 5. SERVICE PROVIDER ID QUALIFIER Blank Not specified 01 National Provider Identifier NPI ; 03 Blue Shield 04 Medicare 06 UPIN 07 NCPDP Provider ID 09 Champus 10 Health Industry number HIN ; 12 Drug Enforcement 13 State Issued Administration DEA ; 99 other 6. CARRIER ID Carrier code assigned in Worker's Compensation Program. 7. CLAIM REFERENCE ID Identifies the claim number assigned by Worker's Compensation Program. 8. PRESCRIPTION SERVICE REFERENCE # QUALIFIER Blank Not specified 1 Rx billing and cromolyn. Beta agonists 334 Beta blockers 33, 46, 47, Beta blockers-cardioselective 283 Beta carotene 9, 315 Beta lactams 311 Betamethasone 229 Bezafibrate 287 Bias 242 Biliary tract disease 125 Bipolar disorder 244, 309 Bisoprolol 76, 91 Bisphosphonates 20, 69, 155, Bladder neoplasms 322 Bleeding cerebrovascular see stroke ; gastrointestinal 1, 44, 49, oesophageal variceal 32 drug induced 9, 19 Bleomycin 200 Blindness 298 Blood 288 Blood coagulation tests 183, 283 Blood glucose 171, 252, 260, Blood pressure 62, 231, 280, Body weight 186, 190, 197, Bone marrow 145 Bone mineral density 151, 154, 228, Bone resorption 326 Botulinum toxin 39, 109, 113 Brain 237, 288 Brain damage 36 Breast diseases 73, 321 Breast 288, 314 Breath tests 257 Bromocriptine 162 Bronchitis 26, 52, 107, Bronchodilators-antimuscarinic 334 Bronchodilators 145, 270, 334 Bucindolol 117 Budesonide 3, 31, 60, Budgets 143 Bulimia 148 Bulletins 103, 215, 222 Buprenorphine 182, 303, 330 Bupropion 154, 160, 163 see also amfebutamone ; Butterbur 242 chemotherapy 10, 145 Chronotherapy 21 childhood 38, 211, 235, CIBIS-II trial 91 colon 9, 61, 167, Ciclosporin 2, 92, 103, colorectal 5, 17, 21, Cidofovir 13 gastric 9, 161, 276 Cimetidine 32 leukaemia 10 Cisappride 63, 142, 149 liver 63 Cisplatin 200, 274, 322 lung 209, 250 Clarithromycin 7 ovarian 37, 60, 71, CLASP trial 99 pancreatic 1, 205 CLASSICS trial 99 prostate 15, 93, 101, Clindamycin 303 skin 1, 17, 120, Clinical governance 291, 340 uterine 272, 331 Clinical pharmacy 96, 116, 329 CAPPP trial 62, 95 Clinical trials 128, 146, 170, Captopril 7, 24, 112, Clodronate 69 CAPRICORN study 207 Clomiphene 333 CAPTURE trial 6 Clopidogrel 80, 99, 152, Carbamazepine 115, 327 286, Cardiac arrest 29, 213, 219, Clozapine 5, 23, 98, Cardiopulmonary resuscitation 232 Coamoxiclav 124, 205 Carbidopa 181 COBALT trial 27 Carbohydrates 309 Cochrane library 67 Carboplatin 274 Codes of practice 217 Cardiomyopathy 132, 209 Cognition disorders 33, 187, 201, Cardiovascular disorders 45, 47, 62, see also dementia ; Colchicine 340 86, 104, Colitis-ulcerative 119 139, 148, Collagen 116 209, 212, Colonic diseases-functional 152 237, 246, Colonic strictures 3 280, 289, Coltec EC 43, 50 304, Combs 170 335 events 13, 15, 17, Common cold 169, 186 Communication 130, 143, 281, Computers 86, 149 system 186 Computerised prescribing 51 CARE trial 14 CONSENSUS II trial 6 Carvedilol 9, 76, 114, Condoms 249 CAST trial 8 Contraceptives, oral 3, 29, 71, Cataracts 11, 70, 141 Catheters, parenteral 50, 166 postcoital 68, 143, 158, CCS-1 trial 6 devices 237, 247 Cefotaxime 7 Controlled dosage systems 337 Ceftriaxone 7 COPERNICUS trial 148, 298 Celecoxib 17, 110, 133, Coronary artery bypass 263, 282, 338 Coronary disease Cerebral ischaemia 235 see also Myocardial Infarction ; , Cerebrovascular disease see stroke ; 2, 4, 5, Cerivastatin 218, 221, 225 Cetirizine 242 151, 156, CFCs 1, 77 186, CHAOS trial 9 206, 214, CHARM trial 78, 327 248, Chelation therapy 5, 245 270, Child 64, 67, 73, Corticosteroids 2, 7, 16, Child behaviour disorders 146, 274 Cabergoline 120 236, 246, Chlamydia 249 CAESAR trial 5 319, 332, Chlorambucil 188 Calcipotriol 154 inhaled 1, 11, 26, Chloramphenicol 48 Calcitonin 105 169, 303, Chloroquine 190 Calcium 20, 231 Cost analysis 127, 134, 192, Chlorofluorocarbons 88 Calcium antagonists 11, 13, 15, Cost control 155 Chlorpromazine 3 54, 62, Cost-effectiveness 2, 5, 7, Chlorthalidone 13, 152 292 Chocolate 171, 237 Candesartan 189, 291, 327 Cough 12, 52, 199, Cholecalciferol 20 Cannabis 145, 336 C-reactive protein 214, 289 Cholesterol 14, 21, 47, Cancer 7, 10, 11, Cranberry 213 208, 220, CREDO trial 99 308, 316 Critical appraisal 54 Cholelithiasis 125 breast 3, 10, 13, Crohn's disease 2, 22, 66, Cholinesterase inhibitors 295 106, 109, Cromoglycate 12 Chondroitin 320, 325 188, Cross reactions 333 Chronic disease 147, 287 318, Croup 60, 70, 121 Chronic obstructive pulmonary disease COPD ; cervix 254, 306, 318 Cryotherapy 288 14, 54, A current awareness bulletin produced for healthcare professionals by North West Medicines Information Service, The Pharmacy Practice Unit, 70 Pembroke Place, Liverpool, L69 3GF. Editor: Jane Ayres. Telephone: 0151 794 8115. E-mail: druginfo liv.ac.
Adding gateways alone cannot guarantee the connectivity of the backbone topology. Once the doorways are added after the clusterheads election in Figure 10 d ; , gateways are again inserted, and the CDS is formed over the original network topology using the CDS construction rules. The stability of the backbone topology is an important goal in TMPO, and is achieved by the following mechanisms. First, the period of willingness adjustment is long to allow enough time to adjust to clusterhead changes. Second, the willingness value is directly related with the speed of nodes. Fast moving nodes get fewer chances to become a clusterhead than slowly moving or static nodes, thus decreasing the possibility of topology changes due to mobility. Third, the willingness value is also related to the remaining energy of the node, so that the clusterhead role is sustained longer and fewer topology changes happen. Forth, except for clusterheads, doorways and gateways are not put in the routing tables built over the CDS, but only provide links between clusterheads. When doorways or gateways fail, there can be other hosts taking over the role, without any routing updates. The transient period between clusterhead connection re-establishment is equal to the delay of the neighbor protocol propagating one-hop neighbor updates. Lastly, nodes change their priorities asynchronously, thus avoiding synchronization problems from clusterhead changes and routing updates and danocrine.
181. Daher Ede F, Brunetta DM, de Silva Junior GB, Puster RA, Patrocinio RM. Pancreatic involvement in fatal human leptospirosis: clinical and histopathological features. Rev Inst Med Trop Sao Paulo 2003; 45: 307-13. [PMID 14762628] 182. Lin XZ, Chen TW, Wang SS, Shiesh SC, Tsai YT, Huang TP, et al. Pancreatic enzymes in uremic patients with or without dialysis. Clin Biochem 1988; 21: 189-92. [PMID 2455611] 183. Tsianos EV, Dardamanis MA, Elisaf M, Vasakos S, Siamopoulos KC. The value of alpha-amylase and isoamylase determination in chronic renal failure patients. Int J Pancreatol 1994; 15: 105-11. [PMID 8071568] 184. Dardamanis MA, Elisaf MS, Vasakos SA, Tsianos EV, Siamopoulos KC. alpha-Amylase and isoamylase levels in renal transplant recipients compared to uremic patients. Ren Fail 1995; 17: 715-9. [PMID 8771244] 185. Duerksen DR, Tsang M, Parry DM. Chronic hyperlipasemia caused by sarcoidosis. Dig Dis Sci 2000; 45: 1545-8. [PMID 11007103] 186. Munk Z, Tolis G, Jones W, Fallen E, McLean P. Pheochromocytoma presenting with pulmonary edema and hyperamylasemia. Can Med Assoc J 1977; 116: 357-9. [PMID 844016] 187. Kim SY, Kim JH, Kim CH, Nam SW, Kim YJ, Kim JI, et al. A case of pheochromocytoma with hyperamylasemia. Korean J Gastroenterol 2003; 42: 172-5. [PMID 14532724] 188. Matsuzaki H, Hata H, Takeya M, Takatsuki K. Establishment and characterization of an amylaseproducing human myeloma cell line. Blood 1988; 72: 978-82. [PMID 2458153] 189. Lopez J, Ulibarrena C, Gonzalez-Porque P, Navas G, Roldan E, Cancelas JA, et al. Amylase-producing Bence Jones multiple myeloma with pancreatitis-like symptoms. Acta Haematol 1993; 90: 99-101. [PMID 7506860] 190. Ross CM, Devgun MS, Gunn IR. Hyperamylasaemia and multiple myeloma. Ann Clin Biochem 2002; 39: 616-20. [PMID 12564849] 191. Tsai YS, Cheng HL, Lin JS, Tong YC, Chang KC. Retroperitoneal plasmacytoma associated with hyperamylasemia. J Urol 1999; 162: 1681-2. [PMID 10524899] 192. Stein L, Bank S, Rai K. Hyperamylasemia and hematologic malignancies. Ann Intern Med 1992; 116: 266-7. [PMID 1370195] 193. Weitzel JN, Pooler PA, Mohammed R, Levitt MD, Eckfeldt JH. A unique case of breast carcinoma producing pancreatic-type isoamylase. Gastroenterology 1988; 94: 519-20. [PMID 2446952], for instance, cat cisapride.
3. LEWIS K. T., STILES M. Management of cat and dog bites. Fam Physician, 1995 Aug, 52 2 ; : 479-85, 489-90. 4. FLEISHER G. R. The management of bite wounds. N Engl J Med, 1999 Jan 14, 340 2 ; : 138-40. 5. MEDEIROS I., SACONATO H. Antibiotic prophylaxis for mammalian bites. Cochrane Database Syst Rev, 2001, 2 ; : CD001738. Review. 6. LUCHANSKY M. A., BERGMAN M. A., DJALDETTI R. B., HERTZEL A. Cat bite in an old patient : is it simple injury ? EJEM, 10 2 ; : 130-132. 7. KANAVEL A. B. Infections of the hand. In : A guide to the surgical treatment of acute and chronic suppurative processes in the fingers, hand, and forearm. 7th ed Philadelphia : Lea & Febiger, 1943 : 241-2. 8. SCHNALL S. B., VU-ROSE T., HOLTOM P. D., DOYLE B., STEVANOVIC M. Tissue pressures in pyogenic flexor tenosynovitis of the finger. JBJS, 1996, 78-B : 793-5. 9. WONGWORAWAT M. D., SCHNALL S. B. Hand infections. Current treatment options in infectious diseases, 2002, 4 : 295-301. 10. CUMMINGS P. Antibiotics to prevent infection in patients with dog bite wounds : a meta-analysis of randomized trials. Ann Emerg Med, 1994 Mar, 23 3 ; : 535-40. 11. DIRE D. J. Cat bite wounds. Risk factors for infection. Ann emerg med, 1991 Sep, 20 9 ; : 973-9. 12. BOLES S. D., SCHMIDT C. C. Pyogenic flexor tenosynovitis. Hand Clin, 1998 Nov, 14 4 ; : 567-78. 13. LILLE S., HAYAKAWA T., NEUMEISTER M. W., BROWN R. E., ZOOK E. G., MURRAY K. Continuous postoperative catheter irrigation is not necessary for the treatment of suppurative flexor tenosynovitis. J Hand Surg Br ; , 2000 Jun, 25 3 ; : 304-7. 14. MONSTREY S. J., VAN DER WERKEN C., KAUER J. M., GORIS R. J. Tendon sheath infections of the hand. Neth J Surg, 1985 Dec, 37 6 ; : 174-8. 15. CORREIRA K. Managing dog, cat, and human bite wounds. JAAPA, 2003 Apr, 16 4 ; : 28-32, 34, 37. KAHN A., ROBERT E., PIETTE D., DE KEUSTER T., LAMOUREUX J., LEVQUE A. Prevalence of dog bites in children : a telephone survey. Eur J Pediatr, 2004, 163 : 424. 17. KEUSTER T. D., LAMOUREUX J., KAHN A. Epidemiology of dog bites : A Belgian experience of canine behaviour and public health concerns. Vet J, 2005 Jun, in press, corrected proof. 18. CHAUDRY M. A., MACNAMARA A. F., CLARK S. Is the management of dog bite wounds evidence based ? A postal survey and review of the literature. Eur J Emerg Med, 2004 Dec, 11 6 ; : 313-7. 19. OSTANELLO F., GHERARDI A., CAPRIOLI A., LA PLACA L., PASSINI A., PROSPERI S. Incidence of injuries caused by dogs and cats treated in emergency departments in a major Italian city. Emerg Med J, 2005, 22 : 260-262. 20. GARBUTT F., JENNER R. Wound closure in animal bites. Emerg Med J, 2004, 21 : 589-590 and stimate.
Fluconazole This agent has been associated with rare cases of serious hepatic injury. Hepatotoxicity associated with fluconazole is usually but not always ; reversible upon discontinuation of the drug. Because fluconazole is cleared mainly by the kidneys, special dosing requirements need to be met for patients receiving multiple doses, but no dose adjustment is needed for single-dose treatment of vaginal candidiasis. Fluconazole is excreted in breast milk, and its use in nursing mothers is not recommended. Fluconazole is a CYP3A4- and CYP2C9inhibitor, so caution should be used with drugs metabolized by these two enzymes. Please see summary sheet for a more detailed list of drug interactions. Flucytosine There are several warnings regarding the use of this agent. Extreme caution is recommended for use in patients with bone marrow depression. In renally impaired patients, accumulation of flucytosine may occur. The manufacturer recommends that electrolytes be determined as well as the hematological and renal status of the patient. Any agent that impairs glomerular filtration may lengthen the half-life of this agent. Itraconazole Itraconazole's labeling contains a black box warning regarding its use in patients with congestive heart failure, evidence of ventricular dysfunction, or a history of CHF. The label also recommends discontinuing treatment for onychomycosis if signs and symptoms of CHF occur during treatment. The boxed warning also addresses drug interactions that can occur when itraconazole is coadministered with cisapride, pimozide, dofetilide, or quinidine. Coadministration is contraindicated because of itraconazole's trait as a potent inhibitor of CYP450 3A4. Coadministration may result in serious cardiovascular events, including QT prolongation, torsades de pointes, ventricular tachycardia, cardiac arrest, and or sudden death. The absorption of itraconazole may be decreased in HIV patients because of hypochlorhydria. Administration with a cola beverage may increase itraconazole absorption. Itraconazole has been associated with rare cases of hepatotoxicity. Use of itraconazole is strongly discouraged in patients with elevated or abnormal liver enzymes or active liver disease. Itraconazole should not be administered to women of child-bearing age unless effective birth control measures are utilized during therapy, as well as for two months after therapy ends. Because itraconazole is a potent inhibitor of CYP3A4, it should be administered cautiously in combination with agents metabolized by this enzyme. Use of the specific agents above, as well as lovastatin and simvastatin, is contraindicated for use by patients on itraconazole therapy. See the summary sheet for a more detailed listing of drug interactions.
Let x t - 3 ; since e sn ; i eevt + 1 ai ; 2, get that the entropy of action j exceeds t - 1 ; with probability at most i 2 exp - 1 x2 i easy to establish that 2, because cisapriee cat.
|